Advertisement

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Mar
10
Today In Oncology
Partial Gland Removal May Be an Option for Many Men With Prostate Cancer
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Greater Plant Based Oil Lower Butter Intake Could Improve Risk of Cancer Related Mortality
Breast Cancer Mortality Rates May Have Stopped Declining
SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo